Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
We have performed a set of independent studies on the effects of the circulating pancreatic polypeptide, amylin, on rat osteoclast function, in vitro. Time‐lapse video observations, measuring cell protrusions and retraction, showed that 250 nmol l‐1 amylin or 250 nmol l‐1 beta‐calcitonin gene‐related peptide (beta‐CGRP) inhibited osteoclast motility (quiescence or Q effect). Both amylin and beta‐CGRP produced inhibitory responses with a significant first‐order regression over time (half‐times, 19 and 28 min respectively). In contrast, 250 nmol l‐1 amylin or 250 nmol l‐1 beta‐CGRP produced no change of osteoclast spread area, whilst 300 pmol l‐1 calcitonin (CT) application resulted in cell retraction (R effect). Forskolin (10 mumol l‐1) mimicked amylin and CGRP in inhibiting osteoclast motility (half‐time, 8.6 min), and similarly lacked an effect on cell spread area. Neither amylin nor beta‐CGRP (62.5–1250 nmol l‐1) elevated cytosolic free calcium levels ([Ca2+]i) in single osteoclasts whilst 300 pmol l‐1 salmon calcitonin (sCT) produced a rapid phasic elevation of [Ca2+]i, confirming previous results with asusuberic (1‐7) eel calcitonin. The osteoclast‐bone resorption assay revealed the following potency difference in direct comparison of the area of resorption per bone slice: beta‐CGRP/amylin, 0.1; sCT/amylin, 800 and human CT/amylin, 12. The potency of deamidated amylin approached that of beta‐CGRP. Assay precision ranged between 0.3 and 0.8. Amylin (250 nmol l‐1) also significantly (P < 0.05) reduced supernatant (tartrate‐resistant) acid phosphatase in the bone‐osteoclast cultures. These measures independently indicate an effect of amylin on osteoclast motility through mechanisms distinct from those of calcitonin, possibly through different selectivities for receptor subtypes, the cyclic AMP‐linked 'amylin subtype' and the [Ca2+]i‐linked 'calcitonin subtype'.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CGRP and amylin reduced osteoclast motility, but only calcitonin reduced both motility and osteoclast retraction.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [4]
In the citing paper
“The authors concluded that CGRP and amylin activate only the cAMP pathway, whereas calcitonin also acts on osteoclasts via changes in intracellular calcium and suggest that this may contribute to the greater potency of calcitonin in inhibiting bone resorption (4, 5).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [4]
Citations
Cites
Nicholson, G. C., Moseley, J. M., Sexton, P. M., Mendelsohn, F. A., & Martin, T. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112584 · Cited by 454
Resorption of bone by isolated rabbit osteoclasts
Chambers, T. J., Revell, P. A., Fuller, K., & Athanasou, N. A. (1984) · Journal of Cell Science · doi:10.1242/jcs.66.1.383 · Cited by 413
Osteoblastic Cells Mediate Osteoclastic Responsiveness to Parathyroid Hormone*
McSHEEHY, P. M. J., & CHAMBERS, T. J. (1986) · Endocrinology · doi:10.1210/endo-118-2-824 · Cited by 407
Lukinius, A., Wilander, E., Westermark, G. T., Engstr�m, U., & Westermark, P. (1989) · Diabetologia · doi:10.1007/bf00285291 · Cited by 371
‘Calcium-activated’ intracellular calcium elevation: A novel mechanism of osteoclast regulation
Zaidi, M., Datta, H. K., Patchell, A., Moonga, B., & MacIntyre, I. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91143-1 · Cited by 213
Self-citationPeptides from the calcitonin genes: molecular genetics, structure and function
Breimer, L. H., MacIntyre, I., & Zaidi, M. (1988) · Biochemical Journal · doi:10.1042/bj2550377 · Cited by 189
Self-citationRat amylin: cloning and tissue-specific expression in pancreatic islets.
Leffert, J. D., Newgard, C. B., Okamoto, H., Milburn, J. L., & Luskey, K. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3127 · Cited by 121
In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit
Datta, H. K., Zaidi, M., Wimalawansa, S. J., Ghatei, M. A., Beacham, J. L., Bloom, S. R., & MacIntyre, I. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92391-7 · Cited by 114
Self-citationInhibition of osteoclastic acid phosphatase abolishes bone resorption
Zaidi, M., Moonga, B. S., Moss, D., & MacIntyre, I. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92405-4 · Cited by 106
Self-citationThe demonstration of vasodilator activity of pancreatic amylin amide in the rabbit.
Brain, S. D., Wimalawansa, S. J., MacIntyre, I., & Williams, T. J. (1990) · Europe PMC (PubMed Central) · Cited by 96
Cited by
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
Hull, R. L., Westermark, G. T., Westermark, P., & Kahn, S. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0405 · Cited by 583
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
“Moreover, effects of IAPP also include the regulation of renal filtration (Harris et al., 1997), calcium homeostasis (Alam et al., 1993), and vasodilatation (Chin et al., 1994).”
BackgroundIn vitro autoradiographic localization of amylin binding sites in rat brain
Sexton, P. M., Paxinos, G., Kenney, M. A., Wookey, P. J., & Beaumont, K. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90388-3 · Cited by 277
Wang, L., Shi, X., Zhao, R., Halloran, B. P., Clark, D. J., Jacobs, C. R., & Kingery, W. S. (2010) · Bone · doi:10.1016/j.bone.2009.11.029 · Cited by 198
The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism
Naot, D., & Cornish, J. (2008) · Bone · doi:10.1016/j.bone.2008.07.003 · Cited by 182
“Calcitonin, CGRP and amylin inhibit osteoclast motility, causing quiescence through a cAMP-dependent mechanism [15,16].”
BackgroundGastric Acid, Calcium Absorption, and Their Impact on Bone Health
Kopic, S., & Geibel, J. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00015.2012 · Cited by 176
“, calcitonin, CGRP, and amylin, share some overlapping functions with regard to osteoclast suppression (16, 229, 1199).”
BackgroundEffects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development
Cornish, J., Callon, K. E., Bava, U., Kamona, S. A., Cooper, G. J. S., & Reid, I. R. (2001) · Bone · doi:10.1016/s8756-3282(01)00494-x · Cited by 173
Lactoferrin - A Novel Bone Growth Factor
Naot, D., Grey, A., Reid, I. R., & Cornish, J. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.2.93 · Cited by 167
Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. L.-H. (2002) · Bone · doi:10.1016/s8756-3282(02)00688-9 · Cited by 151
Self-citationThe Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
“The authors concluded that CGRP and amylin activate only the cAMP pathway, whereas calcitonin also acts on osteoclasts via changes in intracellular calcium and suggest that this may contribute to the greater potency of calcitonin in inhibiting bone resorption (4, 5).”
BackgroundAlam, A. S. (1992) · Endocrinology · doi:10.1210/en.130.6.3617 · Cited by 128
Self-citationComparison of the Effects of Calcitonin Gene-Related Peptide and Amylin on Osteoblasts
Dr. Cornish, J., Callon, K. E., Lin, C. Q., Xiao, C. L., Gamble, G. D., Cooper, G. J. S., & Reid, I. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.8.1302 · Cited by 121
“In contrast, inhibition of osteoclast activity by CGRP and amylin probably involves cAMP as a second messenger((41)) and is not affected by amylin receptor blockers.”
BackgroundMolecular physiology of amylin
Pittner, R. A., Albrandt, K., Beaumont, K., Gaeta, L. S. L., Koda, J. E., Moore, C. X., Rittenhouse, J., & Rink, T. J. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550004 · Cited by 105
Cornish, J., Callon, K. E., King, A. R., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.4.e694 · Cited by 102
“They are striking in that the findings are entirely congruent with the actions of this peptide in isolated osteoclasts (1), in isolated osteoblasts (8), in bone organ culture (7, 16, 21), and after local administration of amylin in vivo (8).”
ResultOsteoclast receptors and signaling
Fattore, A. D., Teti, A. M., & Rucci, N. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.01.011 · Cited by 119
Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo
Cornish, J., Callon, K. E., Coy, D. H., Jiang, N.-Y., Xiao, L., Cooper, G. J. S., & Reid, I. R. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.6.e1113 · Cited by 96
“Amylin is consistently found to inhibit basal and stimulated resorption in organ culture (2, 28, 33) and to reduce the activity of isolated osteoclasts (1).”
BackgroundLerner, U. H., & Persson, E. (2008) · PubMed · Cited by 112
Li, J., Kreicbergs, A., Bergström, J., Stark, A., & Ahmed, M. (2007) · Journal of Orthopaedic Research · doi:10.1002/jor.20406 · Cited by 94
“Inhibition of osteoclastic activity has been demonstrated to occur via cAMP receptor mechanism.(18,19) Other conceivable mechanisms include chemotaxis and/or differentiation of bone cells.”
BackgroundReview: The Diabetic Bone: A Cellular and Molecular Perspective
Blakytny, R., Spraul, M., & Jude, E. B. (2011) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734611400256 · Cited by 103
Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass
Hage, M. P., & Fuleihan, G. E. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2480-9 · Cited by 104
“Amylin was shown to stimulate both human [46] and rodent [47] osteoblast proliferation and activity, to inhibit osteoclast development in mouse bone marrow cultures, and to reduce the activity of mature osteoclasts via increases in intracellular cyclic AMP concentration [48, 49].”
Albrandt, K., Brady, E. M., Moore, C. X., Mull, E., Sierzega, M. E., & Beaumont, K. (1995) · Endocrinology · doi:10.1210/endo.136.12.7588285 · Cited by 88
The role of the sympathetic nervous system in controlling bone metabolism
Togari, A., Arai, M., & Kondo, A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.931 · Cited by 95
“CGRP has been demonstrated to inhibit bone-resorbing activity of isolated osteoclasts [49,50] and calcium release in bone tissue cultures [51,52].”
BackgroundRelationships among body mass, its components, and bone
Reid, I. R. (2002) · BoneKEy-Osteovision · doi:10.1138/2002055 · Cited by 85
Villa, I., Dal Fiume, C., Maestroni, A., Rubinacci, A., Ravasi, F., & Guidobono, F. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00307.2002 · Cited by 82
“Amylin decreases bone resorption by inhibiting the motility of osteoclasts (3), stimulates the proliferation of human and rat osteoblasts (8, 38), and increases bone mass in mice (7).”
BackgroundRole of the endothelial cell in osteoclast control: New perspectives
Zaidi, M., Alam, A. S. M. T., Bax, B. E., Shankar, V. S., Bax, C. M. R., Gill, J. S., Pazianas, M., Huang, C. L.-H., Sahinoglu, T., Moonga, B. S., et al. (1993) · Bone · doi:10.1016/8756-3282(93)90234-2 · Cited by 84
Self-citationCalcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. A., & Sun, Q. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3236828 · Cited by 83
“*is phenomenon might be responsible for the greater potency of calcitonin in the suppression of bone dissociation [126].”
BackgroundWalsh, J., & Henriksen, D. B. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.020 · Cited by 71
CELLULAR BIOLOGY OF BONE RESORPTION
Zaidi, M., Alam, A. S. M. T., Shankar, V. S., Bax, B. E., Bax, C. M. R., Moonga, B. S., Bevis, P. J. R., STEVENS, C., Blake, D. R., Pazianas, M., et al. (1993) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/j.1469-185x.1993.tb00996.x · Cited by 67
Self-citationIshizuka, K., Hirukawa, K., Nakamura, H., & Togari, A. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.046 · Cited by 57
Dissociation of the effects of amylin on osteoblast proliferation and bone resorption
Cornish, J., Callon, K. E., Lin, C. Q.-X., Xiao, C. L., Mulvey, T. B., Coy, D. H., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.5.e827 · Cited by 54
“(1), who found that deamidated amylin was 10-fold less potent in its action on isolated rat osteoclasts than the parent molecule.”
BackgroundResultInfluentialMabilleau, G., Perrot, R., Mieczkowska, A., Boni, S., Flatt, P. R., Irwin, N., & Chappard, D. (2016) · Bone · doi:10.1016/j.bone.2016.07.014 · Cited by 51
Calcitonin Gene Family of Peptides
Becker, K. L., Müller-Stich, B. P., Nylén, E., Cohen, R., White, J. C., & Snider, R. H. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50137-2 · Cited by 51
Effects of Amylin on Human Osteoblast-Like Cells
Villa, I., Rubinacci, A., Ravasi, F., Ferrara, A. F., & Guidobono, F. (1997) · Peptides · doi:10.1016/s0196-9781(97)00056-9 · Cited by 45
Osteoclast function and its control
Zaidi, M., Pazianas, M., Shankar, V., Bax, B. E., Bax, C. M. R., Bevis, P. J. R., Stevens, C. R., Huang, C. L.-H., Blake, D., Moonga, B., et al. (1993) · Experimental Physiology · doi:10.1113/expphysiol.1993.sp003721 · Cited by 54
Self-citationAntiulcer effects of amylin: a review
Самонина, Г. Е., Копылова, Г. Н., Lukjanzeva, G. V., Zhuykova, S. E., Смирнова, Е. А., German, S. V., & Guseva, A. A. (2003) · Pathophysiology · doi:10.1016/j.pathophys.2003.10.008 · Cited by 47
“[1] A.”
BackgroundDiabetogenic effects of salmon calcitonin are attributable to amylin-like activity
Young, A. A., Wang, M.-W., Gedulin, B. R., RINK, T. J., Pittner, R. A., & Beaumont, K. C. (1995) · Metabolism · doi:10.1016/0026-0495(95)90079-9 · Cited by 42
Pros and cons of fatty acids in bone biology
Wauquier, F., Léotoing, L., Philippe, C., Spilmont, M., Coxam, V., & Wittrant, Y. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.03.001 · Cited by 46
Calcitonin: The Other Thyroid Hormone
Inzerillo, A. M., Zaidi, M., & Huang, C. L.-H. (2002) · Thyroid · doi:10.1089/105072502760339352 · Cited by 53
Self-citationPerry, K. J., Quiza, M., Myers, D. E., Morfis, M., Christopoulos, G., & Sexton, P. M. (1997) · Endocrinology · doi:10.1210/endo.138.8.5312 · Cited by 41
“duce CT-like effects on osteoclasts (10), and CGRP-like ac-”
BackgroundReceptors for calcitonin, calcitonin gene related peptide, amylin, and adrenomedullin
Muff, R., Born, W., & Fischer, J. A. (1995) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y95-133 · Cited by 40
Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa
Wojcik, M. H., Meenaghan, E., Lawson, E. A., Misra, M., Klibanski, A., & Miller, K. K. (2010) · Bone · doi:10.1016/j.bone.2009.11.014 · Cited by 39
“Amylin has also been shown to compromise osteoclast motility [16,17] and differentiation [18,19] in rodent cell cultures, and to decrease osteoclast resorptive activity [18,20].”
Trabecular bone structure in patients with primary hyperparathyroidism
Vogel, M., Hahn, M., & Delling, G. (1995) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00192633 · Cited by 39
“There exist a wide variety of agents stimulating motility of osteoclasts [1, 2, 41] and if PTH stimulates in vivo osteoclastic motility, then an unchanged resorption activity of each osteoclast should lead to a decreased depth of resorption lacunae.”
BackgroundReid, I. R. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72567-7 · Cited by 41
“Insulin is co-secreted with amylin, which directly stimulates osteoblast proliferation in vitro and in vivo [8], inhibits osteoclast activity [2], and substantially increases bone volume when administered to adult mice [10].”
BackgroundAmylin and the Integrated Control of Nutrient Influx
Young, A. J. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52004-0 · Cited by 35
Calcitonin: Physiological Actions and Clinical Applications
Inzerillo, A. M., Zaidi, M., & Huang, C. L.-H. (2004) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2004.17.7.931 · Cited by 36
Self-citationYoung, A. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52003-9 · Cited by 39
Amylin increases bone volume but cannot ameliorate diabetic osteopenia
Romero, D. F., Bryer, H. P., Rucinski, B., Isserow, J. A., Buchinsky, F. J., Cvetković, M., Liu, C. C., & Epstein, S. (1995) · Calcified Tissue International · doi:10.1007/bf00298745 · Cited by 35
Amylin in bone conservation current evidence and hypothetical Considerations
Zaidi, M., Shankar, V. S., Huang, C. L.-H., Pazianas, M., & Bloom, S. R. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90095-v · Cited by 30
Self-citationKinins and Neuro-osteogenic Factors
Lerner, U. H., Persson, E., & Lundberg, P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00063-x · Cited by 31
Effects of amylin and adrenomedullin on the skeleton.
Cornish, J., & Reid, I. R. (2001) · PubMed · Cited by 30
Wookey, P. J., Cao, Z., & Cooper, M. E. (1998) · Mineral and Electrolyte Metabolism · doi:10.1159/000057400 · Cited by 28
Effects of Amylin Deficiency on Trabecular Bone in Young Mice Are Sex-Dependent
Davey, R. A., Moore, A. J., Chiu, M. W. S., Notini, A. J., Morris, H. A., & Zajac, J. D. (2006) · Calcified Tissue International · doi:10.1007/s00223-005-0286-2 · Cited by 25
“Amylin inhibits the activity of osteoclastlike cells [7] and stimulates osteoblast proliferation in vitro [8].”
BackgroundZaidi, M., Shankar, V. S., Adebanjo, O. A., Lai, F. A., Pazianas, M., Sunavala, G., Spielman, A. I., & Rifkin, B. R. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.271.3.f637 · Cited by 25
Self-citationKondo, H., Kondo, M., Hayashi, K., Kusafuka, S., Hamamura, K., Tanaka, K., Kodama, D., Hirai, T., Sato, T., Ariji, Y., et al. (2021) · European Journal of Orthodontics · doi:10.1093/ejo/cjab072 · Cited by 23
Short Anabolic Peptides for Bone Growth
Amso, Z., Cornish, J., & Brimble, M. A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21388 · Cited by 21
The neuro-osteogenic network: The sympathetic regulation of bone resorption
Togari, A., Arai, M., Kondo, H., Kodama, D., & Niwa, Y. (2012) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2011.12.002 · Cited by 23
“CGRP has been demonstrated to inhibit the bone-resorbing activity of isolated osteoclasts [66,67], and calcium release in bone tissue cultures [68,69].”
BackgroundResearch progress on osteoclast regulation by biodegradable magnesium and its mechanism
Zhu, W., Wang, W., Yang, X. H., Ran, C., Zhang, T., Shibo, H., Yang, J., Wang, F., Wang, H., Wan, P., et al. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf026 · Cited by 28
“Additionally, amylin and calcitonin have been shown to inhibit OC formation [106, 107].”
The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis
Warrington, J. I., Richards, G. O., & Wang, N. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0071-9 · Cited by 19
Amylin exerts osteogenic actions with different efficacy depending on the diabetic status
Gutiérrez-Rojas, I., Lozano, D., Nuche‐Berenguer, B., Moreno, P., Acitores, A., Ramos-Álvarez, I., Rovira, A., Novials, A., Martín-Crespo, E., Villanueva‐Peñacarrillo, M. L., et al. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.11.013 · Cited by 18
“Moreover, in vitro studies have shown that amylin can inhibit both formation and activity of osteoclasts (Alam et al., 1993; Cornish et al., 2001), and that it also appears to directly affect osteoblasts (Cornish et al., 1995, 1998b; Villa et al., 1997).”
Okamoto, F., Kajiya, H., Fukushima, H., Jimi, E., & Okabe, K. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00551.2003 · Cited by 24
“This phenomenon has been described in terms of motility (1), and we assessed this motility on the basis of the method originally described by Alam et al.”
MethodαCGRP Affects BMSCs’ Migration and Osteogenesis via the Hippo-YAP Pathway
Wang, B., Lin, J., Zhang, Q., Zhang, X., Yu, H., Gong, P., & Xiang, L. (2019) · Cell Transplantation · doi:10.1177/0963689719871000 · Cited by 16
Wang, L., Hou, S., Sabsovich, I., Guo, T., Wei, T., & Kingery, W. S. (2020) · Bone · doi:10.1016/j.bone.2020.115806 · Cited by 15
“The in vitro literature has consistently observed CGRP inhibition of osteoclastogenesis and bone resorption [7, 40-45], but aging CGRP deficient mice have no changes in osteoclast number per surface, osteoclast surface per bone surface, or urinary DPD levels [9].”
BackgroundEnergy metabolism and the skeleton: Reciprocal interplay
Amelio, P. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i11.190 · Cited by 18
Molecular and Clinical Pharmacology of Calcitonin
Zaidi, M., Inzerillo, A. M., Troen, B. R., Moonga, B. S., Abe, E., & Burckhardt, P. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50184-0 · Cited by 16
Self-citationThe effect of tetracyclines on quantitative measures of osteoclast morphology
Zaidi, M., Moonga, B. S., Huang, C. L.-H., Alam, A. S. M. T., Shankar, V. S., Pazianas, M., Eastwood, J. B., Datta, H. K., & Rifkin, B. R. (1993) · Bioscience Reports · doi:10.1007/bf01149962 · Cited by 14
Self-citationAmylin(1–8) is Devoid of Anabolic Activity in Bone
Ellegaard, M., Thorkildsen, C., Petersen, S., Petersen, J. S., Jørgensen, N. R., Just, R., Schwarz, P., Ramírez, M. T., & Stahlhut, M. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9338-3 · Cited by 14
“Amylin(1–37), a pancreatic beta-cell-derived hormone, has been reported to stimulate osteoblast proliferation and bone formation and to inhibit osteoclast-mediated bone resorption [1, 3, 9, 10, 21, 22].”
BackgroundJeevaratnam, K., Salvage, S. C., Li, M., & Huang, C. L.-H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13861 · Cited by 12
Self-citationYoung, A. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52016-7 · Cited by 8
Volumes of chick and rat osteoclasts cultured on glass
Piper, K., BOYDE, A., & Jones, S. J. (1995) · Calcified Tissue International · doi:10.1007/bf00301607 · Cited by 9
Metabolic effects of amylin in lactating goats.
Min, S. H., Farr, V. C., Lee, J., Prosser, C. G., Cooper, G. J. S., & Davis, S. R. (1999) · Journal of Animal Science · doi:10.2527/1999.7751241x · Cited by 8
Pagani, F., Netti, C., GUIDOBONO, F., Lattuada, N., Ticozzi, C., & Sibilia, V. (1998) · Neuroendocrinology · doi:10.1159/000054369 · Cited by 7
Westermark, G. T. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch28 · Cited by 7
Suzuki, H., & Yamamoto, T. (2014) · Tissue and Cell · doi:10.1016/j.tice.2014.10.004 · Cited by 6
Effects of amylin on bone development and egg production in hens
Güzel, S., Gunes, N., Yıldız, H., & Yılmaz, B. (2009) · Poultry Science · doi:10.3382/ps.2008-00256 · Cited by 6
Kinins and Neuro-osteogenic Factors
Lerner, U. H., & Lundberg, P. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50146-3 · Cited by 17
Martin, T. J., Findlay, D. M., Moseley, J. M., & Sexton, P. M. (1998) · Elsevier eBooks · doi:10.1016/b978-012068700-8/50005-0 · Cited by 7
Amylin analogs for the treatment of obesity without diabetes: present and future
Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2409403 · Cited by 5
Identification of a Novel Bone/Calcium Metabolism-regulating Factor in Porcine Pancreas
Izbicka, E., Yoneda, T., Takaoka, Y., Horn, D., Williams, P., & Mundy, G. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23230 · Cited by 5
Purification and Biological Function of Caldecrin
Tomomura, A., Bandow, K., & Tomomura, M. (2021) · Medicines · doi:10.3390/medicines8080041 · Cited by 4
“Glucagon [2,3], amylin [4,5], and calcitonin gene-related peptides [6,7] secreted from the pancreas may be responsible for hypocalcemia.”
BackgroundCalcitonin Gene Family of Peptides
Hu, M. I.-N., & Gagel, R. F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00055-0 · Cited by 4
Physiological and Pathophysiological Role of Islet Amyloid Polypeptide (IAPP, Amylin)
Westermark, G. T. (2011) · Springer eBooks · doi:10.1007/978-1-4419-6956-9_15 · Cited by 4
“Bone absorption is reduced because IAPP slows down the mobility of the osteoclasts [106–108] and prevents the fusion of the preosteoclasts into multinucleated osteoclasts shown in rodent cell culture [109].”
BackgroundAmylin and Related Proteins: Physiology and Pathophysiology
Cooper, G. J. S. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070210 · Cited by 7
Localization of amylin‐like immunoreactivity in the striped velvet gecko pancreas
Suzuki, H., & Yamamoto, T. (2018) · Anatomia Histologia Embryologia · doi:10.1111/ahe.12337 · Cited by 3
Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function
Tomomura, M., & Tomomura, A. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.358 · Cited by 4
In Vitro Regulation of Osteoblast Activity
Karin, N. J., & Farach‐Carson, M. C. (2004) · Springer eBooks · doi:10.1007/978-1-4471-3777-1_2 · Cited by 3
Naot, D., Musson, D. S., & Cornish, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00033-6 · Cited by 4
Amylin and Calcitonin Gene-Related Peptide
Naot, D., Reid, I. R., & Cornish, J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00056-2 · Cited by 2
Periodontitis and peri-implantitis
Wadia, R. (2020) · BDJ · doi:10.1038/s41415-020-1444-7 · Cited by 2
Genetics and Cell Biology of Calcitonin Action
Zaidi, M., Moonga, B. S., Pazianas, M., Shankar, V. S., & Huang, C. L.-H. (1997) · Principles of medical biology · doi:10.1016/s1569-2582(97)80173-0 · Cited by 2
Self-citationMulder, H., Åhrén, B., Ekblad, E., Gebré‐Medhin, S., Betsholtz, C., Sundelin, J., Westermark, G. T., Westermark, P., & Sundler, F. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-695-9_21 · Cited by 1
Amilina: del estudio molecular a las acciones fisiológicas
Rojas, I., & Novials, A. (2001) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(01)74399-9 · Cited by 6
Saha, P. S. (2013) · Journal of biomedical engineering and technology · doi:10.12691/jbet-1-3-4
“By 1998, it was an established concept that amylin possessed an osteoblastic cell proliferation effect along with the antiosteoclastic effect [35,36].”
BackgroundPaulsson, J. F. (2006) · DiVA (Linkoping University)
Bailey, J. A. (2008) · cIRcle (University of British Columbia) · doi:10.14288/1.0066659
“Other physiological functions implied for IAPP are regulation of renal function (43,44), and calcium homeostasis (45,46).”
BackgroundIMPACT DES PEPTIDES GASTRO-INTESTINAUX DANS LA PATHOGÉNÈSE DE L'OBÉSITÉ
Miegueu, P. (2012)
Amylin and Calcitonin Gene-Related Peptide
Reid, I. R., & Cornish, J. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50138-4
Metadata
- Authors
- Alam, A., Moonga, B., Bevis, P., Huang, C., & Zaidi, M.
- Affiliations
- St George's, University of London (GB)
- ORCID
- Zaidi, M
- Venue
- Experimental Physiology
- Publisher
- Wiley
- Published
- 1993-03
- Volume
- 78
- Issue
- 2
- Pages
- 183-196
- ISSN
- 0958-0670 (ISSN-L)
- 1469-445X
- OpenAlex
- W2003780860
- Cited by
- 99
- References
- 17
- Citations by year
- 2025: 1 · 2024: 1 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 4
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Physiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- amylin, bone resorption, calcitonin, cell retraction, cell protrusions, intracellular calcium, cyclic AMP, tartrate-resistant acid phosphatase, pancreatic polypeptide
- MeSH terms
- Cyclic AMP, Amyloid, Animals, Bone Resorption, Calcitonin, Calcium, Cell Movement, Cytosol, Colforsin, Osteoclasts, Calcitonin Gene-Related Peptide, Rats, Wistar, Rats, Islet Amyloid Polypeptide, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.